ESA - Esmolol versus Sufentanil on the quality of recovery after laparoscopic cholecystectomy during anesthesia with oro-tracheal intubation on ambulatory

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520282-31-00

Acronym

87RI_24_0041

Enrollment

120

Registered

2025-05-16

Start date

2025-10-23

Completion date

Unknown

Last updated

2025-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Cholecystectomy

Brief summary

Quality of recovery questionnaire (fQoR-15) on D1 (day after surgery)

Detailed description

1- Cumulative duration of the Visual Analogue Scale (VAS) > 3 and total dose of morphine 2-Presence of pharyngeal pain (= sore throat) in the recovery room and outpatient 3- Blood pressure surge with SBP > 180 mmHg and/or DBP > 110 mmHg 4- Tachycardia with HR > 100 bpm 5- Hypotension with SBP < 90 mmHg and/or DBP < 50 mmHg ), bradycardia with HR < 50 bpm ; Use of vasopressors intraoperatively

Interventions

DRUGESMOCARD 100 mg/10 ml

DRUGsolution injectable

DRUGSufentanil Viatris 5 microgrammes/ml solution injectable

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
1- Cumulative duration of the Visual Analogue Scale (VAS) > 3 and total dose of morphine 2-Presence of pharyngeal pain (= sore throat) in the recovery room and outpatient 3- Blood pressure surge with SBP > 180 mmHg and/or DBP > 110 mmHg 4- Tachycardia with HR > 100 bpm 5- Hypotension with SBP < 90 mmHg and/or DBP < 50 mmHg ), bradycardia with HR < 50 bpm ; Use of vasopressors intraoperatively	—

Primary

Measure	Time frame
Quality of recovery questionnaire (fQoR-15) on D1 (day after surgery)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026